tetano
Editor, Senior Moderator
Cureus
. 2021 Jan 3;13(1):e12455.
doi: 10.7759/cureus.12455.
An Atypical Case of COVID-19 Induced Pancytopenia, Rhabdomyolysis and Myocarditis
Olusayo Fadiran[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory distress coronavirus 2 (SARS-CoV-2) virus is responsible for the current pandemic - coronavirus disease 2019 (COVID-19) plaguing the world. It began spreading as early as January 2020 in the United States (US) and has recently become the leading cause of death amongst adults over 45 years of age. Much of its clinical presentation is already known, and there have been advances in its successful treatment with a food and drug administration (FDA) approved antiviral medication called remdesivir, and other proven investigational methods with clinical benefits including dexamethasone and COVID-19 antibody transfusion called convalescent plasma therapy. However, the recommendations for their use include COVID-19 confirmed patients requiring supplemental oxygen or other forms of respiratory support. In this case report, we describe in detail a unique case of severe COVID-19 infection that did not require any form of oxygen support but was treated successfully with antiviral medications and steroids. The purpose of this report is to highlight in detail an unusual COVID-19 presentation with rhabdomyolysis, myocarditis, and pancytopenia severe enough to require hospitalization and treatment with proven COVID-19 therapy to achieve clinical resolution.
Keywords: covid and myocarditis; covid-19; rhabdomyolysis; “pancytopenia”.
. 2021 Jan 3;13(1):e12455.
doi: 10.7759/cureus.12455.
An Atypical Case of COVID-19 Induced Pancytopenia, Rhabdomyolysis and Myocarditis
Olusayo Fadiran[SUP] 1 [/SUP]
Affiliations
- PMID: 33552773
- PMCID: PMC7853727
- DOI: 10.7759/cureus.12455
Abstract
Severe acute respiratory distress coronavirus 2 (SARS-CoV-2) virus is responsible for the current pandemic - coronavirus disease 2019 (COVID-19) plaguing the world. It began spreading as early as January 2020 in the United States (US) and has recently become the leading cause of death amongst adults over 45 years of age. Much of its clinical presentation is already known, and there have been advances in its successful treatment with a food and drug administration (FDA) approved antiviral medication called remdesivir, and other proven investigational methods with clinical benefits including dexamethasone and COVID-19 antibody transfusion called convalescent plasma therapy. However, the recommendations for their use include COVID-19 confirmed patients requiring supplemental oxygen or other forms of respiratory support. In this case report, we describe in detail a unique case of severe COVID-19 infection that did not require any form of oxygen support but was treated successfully with antiviral medications and steroids. The purpose of this report is to highlight in detail an unusual COVID-19 presentation with rhabdomyolysis, myocarditis, and pancytopenia severe enough to require hospitalization and treatment with proven COVID-19 therapy to achieve clinical resolution.
Keywords: covid and myocarditis; covid-19; rhabdomyolysis; “pancytopenia”.